Muna Therapeutics

Muna Therapeutics is a Copenhagen-based entity operating as a startup studio and investment vehicle focused on novel disease-modifying therapeutics for neurodegenerative diseases. Unlike traditional venture firms, the studio model implies direct involvement in company formation and program development rather than purely external capital provision. The mandate covers biotech and pharma therapeutics, with concentration in conditions such as Alzheimer’s, Parkinson’s, ALS, and related neurodegenerative diseases where biology is complex and clinical translation is difficult. Limited public information is available on a separate investment team distinct from the operating organization, and check sizing is not publicly disclosed in standard ranges, which is consistent with a studio rather than a conventional fund structure.

The entity engages at Pre-Seed and Seed stages, the moment when neurodegenerative programs typically need scientific validation, target engagement work, and early team building. The Denmark base places Muna inside the European biotech ecosystem, with natural ties to Scandinavian academic neuroscience and neighboring research clusters. While not formally bounded geographically, the operating model favors close collaboration, suggesting European programs and partnerships are the strongest natural fit.

For scientific founders and translational investigators, engagement with Muna Therapeutics resembles a deep partnership rather than a check-and-board-seat relationship. The studio approach implies shared work on target selection, preclinical strategy, and company formation, which can be high-value for academic teams without prior company-building experience but requires comfort with closer operational involvement than most venture relationships. Programs that need patient capital and scientific co-development in neurodegeneration are the natural fit; teams seeking arm’s-length capital should look elsewhere.